Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

PhaseRX soars as its lead candidate receives orphan drug status

Monday, November 28, 2016 9:09
% of readers think this story is Fact. Add your two cents.

(Before It's News)

PhaseRx, Inc (NASDAQ:PZRX) shares soared on Monday as the US Food and Drug Administration (FDA) granted its lead candidate drug, PRX-OTC, orphan drug designation.

The designation effectively allows the development of PRX-OTC, which is being developed for the treatment of an inherited liver disease that causes ammonia to accumulate in the blood, to be fast-tracked.

The designation is given to drugs that address diseases or circumstances that occur so infrequently in the USA there is no reasonable expectation that the cost of bringing the drug to market will be recovered from sales.

Orphan drugs qualify for tax credits to offset clinical trials costs, exemptions from certain FDA application fees, and seven years of market exclusivity upon regulatory product approval.

Shares in PhaseRX, which is developing messenger ribonucleic acid (mRNA) treatments for life-threatening inherited liver diseases in children, shot up 124% to US$2.5316 in early deals.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.